Actinium Pharmaceuticals
ATNM
ATNM
58 hedge funds and large institutions have $34.1M invested in Actinium Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
24% less capital invested
Capital invested by funds: $44.8M → $34.1M (-$10.7M)
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Holders
58
Holding in Top 10
–
Calls
$957K
Puts
$546K
Top Buyers
| 1 | +$1.03M | |
| 2 | +$392K | |
| 3 | +$244K | |
| 4 |
Goldman Sachs
New York
|
+$192K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$125K |
Top Sellers
| 1 | -$630K | |
| 2 | -$610K | |
| 3 | -$430K | |
| 4 |
Renaissance Technologies
New York
|
-$358K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$235K |